Back to Directory Steven Douglas Email douglas@email.chop.edu Institution The Children's Hospital of Philadelphia International Maternal Pedistric Adolescent AIDS CTU Title Chief of Immunology Request an Update Affiliated Studies P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded P1034: Comparative trial of protease-containing and protease-sparing HAART regimes DAIDS Number 10043 Research Area Other Study Status Concluded P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded P1080: ARV & Psychiatric Medication Concentrations in HIV Infected & Uninfected Children DAIDS Number 10768 Research Area Brain and Mental Health Study Status Concluded
P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded
P1034: Comparative trial of protease-containing and protease-sparing HAART regimes DAIDS Number 10043 Research Area Other Study Status Concluded
P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded
P1080: ARV & Psychiatric Medication Concentrations in HIV Infected & Uninfected Children DAIDS Number 10768 Research Area Brain and Mental Health Study Status Concluded
